My SciELO
Services on Demand
Journal
Article
Indicators
- Cited by SciELO
- Access statistics
Related links
- Cited by Google
- Similars in SciELO
- Similars in Google
Share
Archivos de la Sociedad Española de Oftalmología
Print version ISSN 0365-6691
Abstract
ALVAREZ-RIVERA, L.G. et al. Coat's disease treated with bevacizumab (Avastin®). Arch Soc Esp Oftalmol [online]. 2008, vol.83, n.5, pp.329-331. ISSN 0365-6691.
Case Report: We report a case of Coats disease in a 10-year-old-girl who presented with a profound visual deficit, exudative retinal detachment, vascular telangiectasias and subretinal lipid, who underwent treatment with an intravitreal injection of bevacizumab (AVASTIN™). Serial examinations documented an involutional response with a reduction of the subretinal fluid, exudates and macular thickness. Discussion: The aetiology of Coats disease remains uncertain, as does its optimal management. Although resolution of a case depends partially on age, and can even occur spontaneously on rare occasions, intravitreal injections of bevacizumab should be considered when planning treatment.
Keywords : Vascular endothelial growth factor; Coats disease; monoclonal antibodies; angiogenesis inhibitors; telangiectatic retinal vessels.